Inside the Clinic: Treating AYA ALL : Episode 8
Opinion
Video
CALBG 10403 in AYA ALL
Author(s):
A panel of experts discusses the use of CALBG 10403 in patients with AYA ALL, highlighting adverse events reported with the regimen and mitigation practices.
EP: 1.Clinical Scenario: A 23-Year-Old Male with AYA ALL
EP: 2.AYA ALL: Overview and Risk Stratification
EP: 3.AYA ALL: Pediatric and Adult Inspired Regimens
EP: 4.AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
EP: 5.Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions
EP: 6.ALL AYA: Coordination of Care
EP: 7.Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL
Now Viewing
EP: 8.CALBG 10403 in AYA ALL
EP: 9.The Potential of Modified Treatment Regimens in AYA ALL
EP: 10.The Future of AYA ALL
Video content above is prompted by the following:
- Discuss the use of CALGB 10403 in AYA ALL. (Stock W et al. Blood 2019)
- Might you have considered a different regimen for this patient?
- Please comment on the key efficacy outcomes.
- What were some AEs reported with this regimen?
- How might you mitigate them?
Related Videos
Related Content
